Literature DB >> 28566837

Massive biventricular rhabdomyoma in a neonate.

Manish Pandey1, Rimlee Dutta2, Shyam S Kothari1.   

Abstract

Rhabdomyoma is a well characterised entity in a neonate. Herein, we report a massive biventricular rhabdomyoma in a neonate presenting with cyanosis and congestive heart failure which was confirmed on autopsy. The report is for documentation of an unusually large tumour.

Entities:  

Keywords:  Everolimus; rhabdomyoma; tuberous sclerosis

Year:  2017        PMID: 28566837      PMCID: PMC5431041          DOI: 10.4103/apc.APC_164_16

Source DB:  PubMed          Journal:  Ann Pediatr Cardiol        ISSN: 0974-5149


Rhabdomyoma as the most common benign cardiac tumor presenting in infancy is a well-characterized entity, and its association with tuberous sclerosis is also well known.[1] Most patients with small tumors are asymptomatic, but some patients may present with arrhythmias, obstruction, and rarely embolism.[2] Spontaneous partial or complete regression of rhabdomyomas during growth is the rule.[13] We recently encountered a 20-day-old neonate in congestive heart failure with cyanosis resulting from massive multiple biventricular rhabdomyoma [Figure 1a and b and Supplementary Videos 1a and b] and wish to document the same in view of its size. The neonate also had macules over the chest suggestive of tuberous sclerosis, but further evaluation could not be performed. He was planned for debulking surgery but had ventricular fibrillation from which he could not be revived. An autopsy confirmed the diagnosis [Figure 2a–c]. More recently, salutary effects of everolimus (mammalian target of rapamycin) in regression of rhabdomyomas have been reported and possibly could have been utilized in this neonate.[45]
Figure 1

(a) Subcostal view. (b) Parasternal short axis

Figure 2

(a) Cardiac rhabdomyoma: Gross picture of the ventricular cavity shows multiple sessile gray-white nodules of varying sizes attached to the ventricular wall (arrows). (b) Microscopy of these nodules revealed a well-demarcated tumorous lesion with adjacent compressed normal myocardium (H and E, ×4). (c) Microscopy of these nodules on high magnification shows classical spider cells (arrow) of rhabdomyoma (H and E, ×20)

(a) Subcostal view. (b) Parasternal short axis (a) Cardiac rhabdomyoma: Gross picture of the ventricular cavity shows multiple sessile gray-white nodules of varying sizes attached to the ventricular wall (arrows). (b) Microscopy of these nodules revealed a well-demarcated tumorous lesion with adjacent compressed normal myocardium (H and E, ×4). (c) Microscopy of these nodules on high magnification shows classical spider cells (arrow) of rhabdomyoma (H and E, ×20)

Videos Available on: www.annalspc.com

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Cardiac rhabdomyomas and obstructive left heart disease: histologically but not functionally benign.

Authors:  M D Black; M Kadletz; J F Smallhorn; R M Freedom
Journal:  Ann Thorac Surg       Date:  1998-05       Impact factor: 4.330

2.  Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect.

Authors:  Ibrahim Mohamed; Guillaume Ethier; Isabelle Goyer; Philippe Major; Nagib Dahdah
Journal:  BMJ Case Rep       Date:  2014-11-26

3.  Regression of a cardiac rhabdomyoma in a patient receiving everolimus.

Authors:  Dana Tiberio; David N Franz; John R Phillips
Journal:  Pediatrics       Date:  2011-04-04       Impact factor: 7.124

4.  Pediatric primary benign cardiac tumors: a 15-year review.

Authors:  M Beghetti; R M Gow; I Haney; J Mawson; W G Williams; R M Freedom
Journal:  Am Heart J       Date:  1997-12       Impact factor: 4.749

5.  Treatment strategies for pediatric patients with primary cardiac and pericardial tumors: a 30-year review.

Authors:  Thomas Günther; Christian Schreiber; Christian Noebauer; Andreas Eicken; Ruediger Lange
Journal:  Pediatr Cardiol       Date:  2008-07-04       Impact factor: 1.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.